Maher Masoud's most recent trade in MaxCyte Inc was a trade of 347,500 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 14, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
MaxCyte Inc | Maher Masoud | Director, President and CEO | 14 Mar 2025 | 347,500 | 347,500 | - | - | Employee Stock Option (right to buy) | ||
MaxCyte Inc | Maher Masoud | Executive Director,President and Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.90 per share. | 10 Jun 2024 | 70,443 | 100,000 (0%) | 0% | 4.9 | 345,248 | Ords 0.01p |
MaxCyte Inc | Maher Masoud | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 4.90 per share. | 07 Jun 2024 | 70,443 | 100,000 | - | 4.9 | 345,241 | Common Stock |
MaxCyte Inc | Maher Masoud | Executive Director,President and Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 4.87 per share. | 07 Jun 2024 | 29,557 | 29,557 (0%) | 0% | 4.9 | 143,824 | Ords 0.01p |
MaxCyte Inc | Maher Masoud | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 4.87 per share. | 07 Jun 2024 | 29,557 | 29,557 | - | 4.9 | 143,824 | Common Stock |
MaxCyte Inc | Maher Masoud | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 400,000 | 400,000 | - | - | Employee Stock Option (right to buy) |